[
  {
    "ts": null,
    "headline": "Eli Lilly Stock Tracking Longest Win Streak Since 2023. What’s Behind the Gains.",
    "summary": "Eli Lilly Stock Tracking Longest Win Streak Since 2023. What’s Behind the Gains.",
    "url": "https://finnhub.io/api/news?id=b12ba6e2e3ffa01a534f34cfd5621f86061df820d7211579896e5d0aff706034",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740577680,
      "headline": "Eli Lilly Stock Tracking Longest Win Streak Since 2023. What’s Behind the Gains.",
      "id": 132881605,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Stock Tracking Longest Win Streak Since 2023. What’s Behind the Gains.",
      "url": "https://finnhub.io/api/news?id=b12ba6e2e3ffa01a534f34cfd5621f86061df820d7211579896e5d0aff706034"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to spend $27 billion to expand U.S. manufacturing with four new sites",
    "summary": "Eli Lilly to spend $27 billion to expand U.S. manufacturing with four new sites",
    "url": "https://finnhub.io/api/news?id=56c0a9cbf3d8814c95d87ec0d7a75a4c0c2f450b99e94b979f18445e5c81e516",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740570780,
      "headline": "Eli Lilly to spend $27 billion to expand U.S. manufacturing with four new sites",
      "id": 132881606,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly to spend $27 billion to expand U.S. manufacturing with four new sites",
      "url": "https://finnhub.io/api/news?id=56c0a9cbf3d8814c95d87ec0d7a75a4c0c2f450b99e94b979f18445e5c81e516"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Plans to Spend $27 Billion on New U.S. Plants",
    "summary": "Eli Lilly Plans to Spend $27 Billion on New U.S. Plants",
    "url": "https://finnhub.io/api/news?id=7e33fe463e57426730c3783b5f6d98994936a8ccb773e26abe44b9ed83d4543a",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740564840,
      "headline": "Eli Lilly Plans to Spend $27 Billion on New U.S. Plants",
      "id": 132881585,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Eli Lilly Plans to Spend $27 Billion on New U.S. Plants",
      "url": "https://finnhub.io/api/news?id=7e33fe463e57426730c3783b5f6d98994936a8ccb773e26abe44b9ed83d4543a"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Oncology Strength: Beating Wall Street Again",
    "summary": "Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.",
    "url": "https://finnhub.io/api/news?id=48cc045b6210dbf5fc551d979a18cc216581d878f6df5c6d273d0c4b6879a62b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740561344,
      "headline": "Merck's Oncology Strength: Beating Wall Street Again",
      "id": 132878313,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/151810706/image_151810706.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.",
      "url": "https://finnhub.io/api/news?id=48cc045b6210dbf5fc551d979a18cc216581d878f6df5c6d273d0c4b6879a62b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly cuts price of weight-loss drug Zepbound as competition heats up",
    "summary": "Eli Lilly cuts price of weight-loss drug Zepbound as competition heats up",
    "url": "https://finnhub.io/api/news?id=41cb656ecc48f93cd58440f328ed21fb7770da22865ab4fbe22fa5ab1b233aee",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740553560,
      "headline": "Eli Lilly cuts price of weight-loss drug Zepbound as competition heats up",
      "id": 132881607,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly cuts price of weight-loss drug Zepbound as competition heats up",
      "url": "https://finnhub.io/api/news?id=41cb656ecc48f93cd58440f328ed21fb7770da22865ab4fbe22fa5ab1b233aee"
    }
  },
  {
    "ts": null,
    "headline": "Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation",
    "summary": "Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read why MTSR stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=3acafc2fbf41e90cba0188207b9ea03754262c0a407534916c76618238a2c368",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740542141,
      "headline": "Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation",
      "id": 132876496,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2183067289/image_2183067289.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read why MTSR stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=3acafc2fbf41e90cba0188207b9ea03754262c0a407534916c76618238a2c368"
    }
  }
]